Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02820116
What this trial is testing

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
Beijing Haidian Hospital 67
Large-scale testing (Phase 3)UnknownNCT04239833
What this trial is testing

SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 240
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Not applicableStudy completedNCT00899756
What this trial is testing

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Testing effectiveness (Phase 2)Ended earlyNCT05215951
What this trial is testing

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07063329
What this trial is testing

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Avistone Pharmaceutical（Ningbo）Co., LTD. 108
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Early research (Phase 1)UnknownNCT03827070
What this trial is testing

Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non Small Cell Lung Cancer
Center Trials & Treatment Europe 12
Testing effectiveness (Phase 2)UnknownNCT05068024
What this trial is testing

FWD1509 in Adults With Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Forward Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT03940703
What this trial is testing

Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Who this might be right for
Non-small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 140
Large-scale testing (Phase 3)Study completedNCT01544179
What this trial is testing

IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 265
Large-scale testing (Phase 3)UnknownNCT02140333
What this trial is testing

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

Who this might be right for
NSCLCEGFR Mutation
The First Affiliated Hospital of Guangzhou Medical University 220
Large-scale testing (Phase 3)Looking for participantsNCT07183189
What this trial is testing

SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 576
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Testing effectiveness (Phase 2)Study completedNCT01217619
What this trial is testing

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Who this might be right for
Non Small Cell Lung Cancer
Baohui Han 25
Testing effectiveness (Phase 2)UnknownNCT03706287
What this trial is testing

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Who this might be right for
Lung Cancer Metastatic
Sichuan Cancer Hospital and Research Institute 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06918782
What this trial is testing

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Who this might be right for
Lung Cancer (NSCLC)
The University of Hong Kong 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Next Page
480